<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619562</url>
  </required_header>
  <id_info>
    <org_study_id>NS10285</org_study_id>
    <nct_id>NCT05619562</nct_id>
  </id_info>
  <brief_title>Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients</brief_title>
  <official_title>Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Institute of Molecular and Translational Medicine, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Institute of Molecular and Translational Medicine, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the presence of circulating/disseminated tumour cells (CTCs/DTCs) in the&#xD;
      blood and bone marrow of the resectable lung cancer (NSCLC) patients is a negative prognostic&#xD;
      factor, and to find correlations with other clinical/pathological disease characteristics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells in lung cancer patients</measure>
    <time_frame>30 days</time_frame>
    <description>The absolute gene expression of CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells(CTCs) isolated from peripheral blood, tumour draining blood and bone marrow samples of lung cancer patients will be measured using real-time RT-PCR method. The gene expression will be normalized per microgram of total mRNA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer specific survival in CTC positive NSCLC patients</measure>
    <time_frame>5 years</time_frame>
    <description>The cancer specific survival, overall survival and disease free survival will be measured from the time of diagnosis to the time of event. Two groups of patients will be compared:&#xD;
A: Patients with the presence of CTCs in peripheral blood, tumour draining blood and bone marrow before NSCLC surgery as described in primary outcome measure.&#xD;
B: Patients with the absence e of CTCs in peripheral blood, tumour draining blood and bone marrow before NSCLC surgery as described in primary outcome measure.</description>
  </secondary_outcome>
  <enrollment type="Actual">166</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Circulating Tumor Cell</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Device for CTC/DTC detection</intervention_name>
    <description>The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      ctDNA from plasma blood samples. DNA and RNA from nucleated blood cells. DNA and RNA from&#xD;
      tumour tissue.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed non-metastatic NSCLC undergoing radical surgery with curative&#xD;
        intent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Non-small cell lung cancer, non-metastatic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Prior neoadjuvant chemoradiotherapy Prior lung cancer Cancer duplicity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marian Hajduch, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <state>Česká Republika</state>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Institute of Molecular and Translational Medicine, Czech Republic</investigator_affiliation>
    <investigator_full_name>Marian Hajduch, M.D., Ph.D.</investigator_full_name>
    <investigator_title>IMTM director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The anonymized metadata will be publicly available after publishing the results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

